Do Traders Think Astria Therapeutics Inc (ATXS) Can Keep Climbing Tuesday?

Overall market sentiment has been high on Astria Therapeutics Inc (ATXS) stock lately. ATXS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Astria Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATXS!

See Full ATXS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATXS Stock Today?

Astria Therapeutics Inc (ATXS) stock is trading at $7.60 as of 3:36 PM on Tuesday, Dec 26, an increase of $0.81, or 11.93% from the previous closing price of $6.79. The stock has traded between $6.93 and $7.75 so far today. Volume today is below average. So far 376,225 shares have traded compared to average volume of 554,459 shares.

More About Astria Therapeutics Inc

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Click Here to get the full Stock Report for Astria Therapeutics Inc stock.